These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14977433)

  • 1. Regarding the development and practice of cascade impaction testing, including a mass balance failure investigation tree.
    Mitchell JP;
    J Aerosol Med; 2003; 16(4):433. PubMed ID: 14977433
    [No Abstract]   [Full Text] [Related]  

  • 2. Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree.
    Christopher D; Curry P; Doub B; Furnkranz K; Lavery M; Lin K; Lyapustina S; Mitchell J; Rogers B; Strickland H; Tougas T; Tsong Y; Wyka B;
    J Aerosol Med; 2003; 16(3):235-47. PubMed ID: 14572321
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of tubing deposition, breathing pattern, and temperature on aerosol mass distribution measured by cascade impactor.
    Gurses BK; Smaldone GC
    J Aerosol Med; 2003; 16(4):387-94. PubMed ID: 14977429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations.
    Mitchell JP; Nagel MW
    J Aerosol Med; 2003; 16(4):341-77. PubMed ID: 14977427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aerosols and devices.
    Dolovich MB; Fink JB
    Respir Care Clin N Am; 2001 Jun; 7(2):131-73, v. PubMed ID: 11517019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory drug delivery.
    Anderson PJ
    Chest; 1997 May; 111(5):1155-6. PubMed ID: 9149560
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro measurements of delivery of medications from MDIs and spacer devices.
    Dolovich M
    J Aerosol Med; 1996 Mar; 9 Suppl 1():S49-58. PubMed ID: 10160058
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols.
    Alexander BD; Winkler TP; Shi S; Dodds Ashley ES; Hickey AJ
    Pharm Dev Technol; 2011; 16(6):577-82. PubMed ID: 21699390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and testing of aerosol delivery systems for reproducible clinical performance.
    Cipolla DC; Farr SJ; Gonda I; Herst CV; Lee RY; Lloyd P; McKinley G; Rubsamen R; Schuster J; Zellhoefer C
    J Aerosol Med; 1998; 11 Suppl 1():S84-8. PubMed ID: 10180738
    [No Abstract]   [Full Text] [Related]  

  • 10. Deposition of aerosols in infants and children.
    Schüepp KG; Straub D; Möller A; Wildhaber JH
    J Aerosol Med; 2004; 17(2):153-6. PubMed ID: 15294065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosol drug delivery: developments in device design and clinical use.
    Rottier B; Grasmeijer F; Hagedoorn P; de Boer AH
    Lancet; 2011 Sep; 378(9795):981-2; author reply 982. PubMed ID: 21907858
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterisation of particle deposition and penetration from nasal sprays.
    Med Device Technol; 2004 Mar; 15(2):39. PubMed ID: 15154338
    [No Abstract]   [Full Text] [Related]  

  • 13. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
    Vecellio L; Abdelrahim ME; Montharu J; Galle J; Diot P; Dubus JC
    J Cyst Fibros; 2011 Mar; 10(2):86-92. PubMed ID: 21075063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two approaches for treating cascade impaction mass balance measurements.
    Wyka B; Tougas T; Mitchell J; Strickland H; Christopher D; Lyapustina S
    J Aerosol Med; 2007; 20(3):236-56. PubMed ID: 17894532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrepancy between in vitro and in vivo dose variability for a pressurized metered dose inhaler and a dry powder inhaler.
    Borgström L; Asking L; Beckman O; Bondesson E; Källén A; Olsson B
    J Aerosol Med; 1998; 11 Suppl 1():S59-64. PubMed ID: 10180734
    [No Abstract]   [Full Text] [Related]  

  • 16. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: Archival calibration.
    Marple VA; Olson BA; Santhanakrishnan K; Mitchell JP; Murray SC; Hudson-Curtis BL
    J Aerosol Med; 2003; 16(3):301-24. PubMed ID: 14572327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardization issues: in vitro assessment of nebulizer performance.
    Dennis JH
    Respir Care; 2002 Dec; 47(12):1445-55; discussion 1455-8. PubMed ID: 12467502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro characterisation of the nebulised dose during non-invasive ventilation.
    Abdelrahim ME; Plant P; Chrystyn H
    J Pharm Pharmacol; 2010 Aug; 62(8):966-72. PubMed ID: 20663030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-impactor-based methods for sizing of aerosols emitted from orally inhaled and nasal drug products (OINDPs).
    Mitchell J; Bauer R; Lyapustina S; Tougas T; Glaab V
    AAPS PharmSciTech; 2011 Sep; 12(3):965-88. PubMed ID: 21785912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of laser diffraction method as a substitute for cascade impaction in the European Project for a Nebulizer Standard.
    Vecellio None L; Grimbert D; Becquemin MH; Boissinot E; Le Pape A; Lemarié E; Diot P
    J Aerosol Med; 2001; 14(1):107-14. PubMed ID: 11495481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.